Immunomodulation and Vaccines
Lead Research Organisation:
London School of Hygiene & Tropical Medicine
Department Name: UNLISTED
Abstract
Human beings evolved in the presence of exposure to many infectious diseases, including viruses, bacteria and worms. Our immune systems evolved to protect us from these agents. However, some of them have develop strategies to evade or regulate the human immune response in such a way that they can live in their human hosts for decades, or for life. These include some parasites (worms, malaria) the bacteria that live in our gut and on our skin, and some viruses. In populations where infectious diseases have become uncommon it is likely that our immune systems develop differently compared to populations where infections are still common. This may have both benefits and disadvantages. We are investigating the hypothesis that exposure to infections, and especially chronic parasitic infections, alters
1. Responses to vaccines – generally in an adverse way, reducing desired, protective vaccine responses
2. Responses to viruses which cause cancer – also reducing beneficial immune responses that control them
3. Susceptibility to asthma and allergy
4. Susceptibility to diabetes
We think that treating parasitic infections effectively may improve the response to vaccines and other infections, but increase the risk of allergy-related diseases and diabetes. Our studies are designed to find out whether this is so.
1. Responses to vaccines – generally in an adverse way, reducing desired, protective vaccine responses
2. Responses to viruses which cause cancer – also reducing beneficial immune responses that control them
3. Susceptibility to asthma and allergy
4. Susceptibility to diabetes
We think that treating parasitic infections effectively may improve the response to vaccines and other infections, but increase the risk of allergy-related diseases and diabetes. Our studies are designed to find out whether this is so.
Technical Summary
Our goal is to understand the impact of infection exposure on human immunological programming and health. Our overarching hypothesis is that chronic and cumulative infection exposure influences immunological mechanisms through active processes (during current infection), lasting epigenetic modifications, and genetic selection; that (therefore) some effects do not immediately respond to treatment; and that effects critically impact upon major health outcomes including vaccine responses and susceptibility to pathogens, allergy-related disease and metabolic conditions (Figure 8.8).
The main focus of our work is on vaccine responses, addressing the role of infectious exposures in striking population differences in vaccine immunogenicity. We also support studies on the role of chronic infection in allergy-related and metabolic disease susceptibility. Building on recent findings, exploiting unique platforms that we have established, we aim to determine the effects of infectious exposures (prenatal, cumulative life-time and current, active exposures) on health outcomes comprising:
1. Vaccine immunogenicity
2. Infectious disease susceptibility – focussing on oncogenic viruses
3. Asthma phenotypes and allergy-related effector mechanisms
4. Infection, inflammation and cardio-metabolic risk
To obtain deeper insights into mechanisms by which infections have their effects, we plan complementary studies (for which funding is available, or being sought elsewhere) on the mediating role of the microbiome and on the mediating role of epigenetic modifications
In addition, the programme supports related studies on tuberculosis and schistosomiasis, and genetic studies.
The main focus of our work is on vaccine responses, addressing the role of infectious exposures in striking population differences in vaccine immunogenicity. We also support studies on the role of chronic infection in allergy-related and metabolic disease susceptibility. Building on recent findings, exploiting unique platforms that we have established, we aim to determine the effects of infectious exposures (prenatal, cumulative life-time and current, active exposures) on health outcomes comprising:
1. Vaccine immunogenicity
2. Infectious disease susceptibility – focussing on oncogenic viruses
3. Asthma phenotypes and allergy-related effector mechanisms
4. Infection, inflammation and cardio-metabolic risk
To obtain deeper insights into mechanisms by which infections have their effects, we plan complementary studies (for which funding is available, or being sought elsewhere) on the mediating role of the microbiome and on the mediating role of epigenetic modifications
In addition, the programme supports related studies on tuberculosis and schistosomiasis, and genetic studies.
Organisations
- London School of Hygiene & Tropical Medicine (Lead Research Organisation)
- Uganda National Expanded Programme on Immunisation (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- University of Manchester (Collaboration)
- Leiden University Medical Center (Collaboration)
- UNIVERSITY OF GLASGOW (Collaboration)
- Wellcome Trust (Collaboration)
- University of the Witwatersrand (Collaboration)
- Uganda Virus Research Institute (Collaboration)
- Texas Tech University Health Sciences Center (Collaboration)
- Uganda Christian University (Collaboration)
- Ministry of Health, Uganda (Collaboration)
People |
ORCID iD |
Publications
Cresswell FV
(2020)
A Journey of Hope: giving research participants a voice to share their experiences and improve community engagement around advanced HIV disease in Uganda.
in AAS open research
Koopman JP
(2019)
Risk assessment for the implementation of controlled human Schistosoma mansoni infection trials in Uganda.
in AAS open research
Andia Biraro I
(2021)
Analysis of the MUII-plus mentorship programme: reflections of Fellows' experiences and lessons for other programmes
in AAS Open Research
Andia Biraro I
(2020)
Analysis of the MUII-plus mentorship programme: reflections of Fellows' experiences and lessons for other programmes
in AAS Open Research
Nyangiri OA
(2021)
Candidate gene family-based and case-control studies of susceptibility to high Schistosoma mansoni worm burden in African children: a protocol.
in AAS open research
Cresswell F
(2020)
A Journey of Hope: giving research participants a voice to share their experiences and improve community engagement around advanced HIV disease in Uganda
in AAS Open Research
Related Projects
| Project Reference | Relationship | Related To | Start | End | Award Value |
|---|---|---|---|---|---|
| MC_UU_00027/1 | 01/02/2018 | 31/03/2023 | £2,855,127 | ||
| MC_UU_00027/2 | Transfer | MC_UU_00027/1 | 01/02/2018 | 31/03/2023 | £1,326,187 |
| MC_UU_00027/3 | Transfer | MC_UU_00027/2 | 01/02/2018 | 31/03/2023 | £1,829,053 |
| MC_UU_00027/4 | Transfer | MC_UU_00027/3 | 01/02/2018 | 31/03/2023 | £959,532 |
| MC_UU_00027/5 | Transfer | MC_UU_00027/4 | 01/02/2018 | 31/03/2023 | £932,836 |
| Description | Meetings with the Ministry of Health on Ebola Vaccine trials |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| Description | "A multi-centre Phase III double-blind, randomized, controlled study to evaluate the efficacy and safety of VPM1002 in comparison to BCG" |
| Amount | € 12,493,179 (EUR) |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 05/2018 |
| Description | African Academy of Sciences grant: Impact of co-infections and host genetics on susceptibility to SARS-CoV-2 infection and COVID-19 disease severity in well-studied cohorts in Uganda (CoHost) |
| Amount | $199,945 (USD) |
| Funding ID | SARSCov2-3-20-002 |
| Organisation | MRC/UVRI Uganda Research Unit on AIDS |
| Sector | Public |
| Country | Uganda |
| Start | 03/2021 |
| End | 02/2023 |
| Description | HIC-VAC pump priming grant with Meta Roestenberg "Preparing for Schistosoma mansoni controlled human infection studies in Uganda" |
| Amount | £89,563 (GBP) |
| Organisation | Imperial College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Human infection studies for Schistosoma mansoni vaccine testing in Uganda |
| Amount | £640,968 (GBP) |
| Funding ID | 218454/Z/19/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 10/2024 |
| Description | Human infection studies for Schistosoma mansoni vaccine testing in Uganda |
| Amount | £30,000 (GBP) |
| Funding ID | 215993 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2019 |
| End | 11/2019 |
| Description | Masters Training Fellowship for Agnes Mutua: "Investigating the influence of vitamin D status on cognitive and motor development in young African children" (role, sponsor) |
| Amount | £119,212 (GBP) |
| Funding ID | 209640 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | NIHR Global Health Groupon on vaccines for vulnerable people in Africa (VAnguard) |
| Amount | £2,984,447 (GBP) |
| Funding ID | NIHR134531 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2022 |
| End | 02/2026 |
| Description | Population differences in vaccine response: the role, reversibility and mediators of immunomodulation by chronic parasitic infections in the tropics |
| Amount | £2,319,188 (GBP) |
| Funding ID | MR/R02118X/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 04/2022 |
| Description | Supplement to MRC Programme Grant, Population differences in vaccine response: the role, reversibility and mediators of immunomodulation by chronic parasitic infections |
| Amount | £200,000 (GBP) |
| Funding ID | MC_PC 21034 |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2022 |
| End | 04/2023 |
| Description | Tropical Medicine Research Centers: Uganda Schistosomiasis Multidisciplinary Research Center |
| Amount | $2,653,173 (USD) |
| Funding ID | U01AI168609 |
| Organisation | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sector | Public |
| Country | United States |
| Start | 05/2022 |
| End | 04/2027 |
| Description | Wellcome International Training Fellowship for Gyaviira Nkurunungi: "The impact of differential parasite exposure on immunological and metabolic predictors of vaccine response in the tropics" |
| Amount | £296,299 (GBP) |
| Funding ID | 224263/Z/21/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2022 |
| End | 03/2025 |
| Title | Educational materials on CHI-S |
| Description | (Please note, our tool does not exactly fit the categories above!). We developed and tested educational materials for potential participants in CHI-S studies. A publication is in preparation. |
| Type Of Material | Model of mechanisms or symptoms - human |
| Year Produced | 2019 |
| Provided To Others? | No |
| Impact | Will be used in future studies |
| Description | Afzal Siddiqui, Texas Tech University Health Sciences Center |
| Organisation | Texas Tech University Health Sciences Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | We have developed a funding proposal to be supported by the Wellcome Trust for establishment of a Controlled Human Infection model for Schistosomiasis (CHI-S) in Uganda. Together with Meta Roestenberg and colleagues, we held a meeting in Leiden to discuss the proposed work. |
| Collaborator Contribution | Dr Siddiqui and colleagues have developed a candidate vaccine which we plan to test using the CHI-S model |
| Impact | The grant application was recommended for funding by the Wellcome Trust panel; details of the award are in the final stages of negotiation |
| Start Year | 2019 |
| Description | Arbovirology, UVRI |
| Organisation | Uganda Virus Research Institute |
| Department | Department of Arbovirology, Emerging and Re-emerging Infections |
| Country | Uganda |
| Sector | Public |
| PI Contribution | We are conducting the POPVAC research programme, samples from which will be processed by the department of arbovirology at UVRI |
| Collaborator Contribution | They will undertake yellow fever plaque reduction neutralisation tests. |
| Impact | Not yet |
| Start Year | 2020 |
| Description | Co-supervision with colleagues from Witwatersrand |
| Organisation | University of the Witwatersrand |
| Department | School of Public Health |
| Country | South Africa |
| Sector | Academic/University |
| PI Contribution | We are jointly supervising PhD student Lawrence Lubyayi who is using data form this project for his PhD |
| Collaborator Contribution | We are jointly supervising PhD student Lawrence Lubyayi who is using data form this project for his PhD |
| Impact | Draft paper |
| Start Year | 2017 |
| Description | Edridah Tukahebwa, Narcis Kabatereine |
| Organisation | Ministry of Health, Uganda |
| Department | Vector Control Division |
| Country | Uganda |
| Sector | Public |
| PI Contribution | These collaborators have expertise in the epidemiology, diagnosis and control of helminth infections. They also understand policy implications and applications. We have worked with them on implementation of all our helminth related work in Uganda. |
| Collaborator Contribution | These collaborators have expertise in the epidemiology, diagnosis and control of helminth infections. They also understand policy implications and applications. |
| Impact | Numerous papers and presentations Stakeholders' meetings Grants |
| Description | Helen McShane, Adrian Hill, Alex Mentzer |
| Organisation | University of Oxford |
| Department | Jenner Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaboration on (1) genetic studies on the response to infant vaccines (on-going) (2) a trial investigating the impact of schistosomiasis on the response to candidate TB vaccine MVA85A (completed) (3) a trial of ChAdOx1 85A and MVA85A as a new regimen for boosting TB immunity in adolescents. We are conducting the trial in Uganda (about to start) |
| Collaborator Contribution | For (1) the partners provide expertise in genetics For (2) and (3) the partners are providing the vaccine, as well as contributing expertise in TB vaccine trials |
| Impact | Publications and conference presentations DPhil for Alex Mentzer (completed) Contributions to PhDs for Swaib Lule (completed), Anne Wajja (on-going) and Beatrice Nassanga (about to commence) |
| Start Year | 2017 |
| Description | Maria Yazdanbakhsh; Meta Roestenberg |
| Organisation | Leiden University Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | We are undertaking collaborations with LUMC department of parasitology on immuno-epidemiological effects of helminths, and on schistosomiasis vaccine development including controlled human infection models for schistosomiasis (CHI-S) In 2019 we developed a proposal for establishing the CHI-S in Uganda which the Wellcome Trust panel supported for funding. We are awaiting the award letter. |
| Collaborator Contribution | The partners provide technical expertise, particularly in parasite immunology and |
| Impact | PhD: co-supervision to completion of two fellows, Gyaviira Nkurunungi and Moses Egesa (both completed successfully in 2019). Publications and conference presentations. New grants for preparatory work on Sm-CHI |
| Start Year | 2011 |
| Description | MoH UNEPI programme |
| Organisation | Uganda National Expanded Programme on Immunisation |
| Country | Uganda |
| Sector | Public |
| PI Contribution | We are running the POPVAC trials which will provide EPI with information on the effects of parasitic infections on the response to widely used vaccines. |
| Collaborator Contribution | The EPI programme is providing HPV vaccine for individuals in the POPVAC trials. As well, they are supporting us with training and advice. |
| Impact | None as yet |
| Start Year | 2018 |
| Description | NIHR Global Health Group, VAnguard |
| Organisation | Uganda Christian University |
| Country | Uganda |
| Sector | Academic/University |
| PI Contribution | This is a new Global Health Group which I lead together with Professor Pontiano Kaleebu, taking forward our work on optimising vaccine benefits for vulnerable populations in Africa. |
| Collaborator Contribution | Partners are leading various work packages |
| Impact | No outputs yet. |
| Start Year | 2022 |
| Description | NIHR Global Health Group, VAnguard |
| Organisation | Uganda Virus Research Institute |
| Country | Uganda |
| Sector | Public |
| PI Contribution | This is a new Global Health Group which I lead together with Professor Pontiano Kaleebu, taking forward our work on optimising vaccine benefits for vulnerable populations in Africa. |
| Collaborator Contribution | Partners are leading various work packages |
| Impact | No outputs yet. |
| Start Year | 2022 |
| Description | NIHR Global Health Group, VAnguard |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This is a new Global Health Group which I lead together with Professor Pontiano Kaleebu, taking forward our work on optimising vaccine benefits for vulnerable populations in Africa. |
| Collaborator Contribution | Partners are leading various work packages |
| Impact | No outputs yet. |
| Start Year | 2022 |
| Description | NIHR Global Health Group, VAnguard |
| Organisation | Wellcome Trust |
| Department | KEMRI-Wellcome Trust Research Programme |
| Country | Kenya |
| Sector | Academic/University |
| PI Contribution | This is a new Global Health Group which I lead together with Professor Pontiano Kaleebu, taking forward our work on optimising vaccine benefits for vulnerable populations in Africa. |
| Collaborator Contribution | Partners are leading various work packages |
| Impact | No outputs yet. |
| Start Year | 2022 |
| Description | Richard Grencis |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Together with Prof Grencis, we won a Royal Society Collaborative Award to support further work on the metabolic impacts of helminth infection. We contribute studies in humans populations |
| Collaborator Contribution | Prof Grencis and colleagues support work in the mouse model, as well as training for Ugandan scientists. |
| Impact | A Masters degree in Bioinformatics form the University of Manchester for Bridgious Walusimbi |
| Start Year | 2016 |
| Description | Sarah Atkinson |
| Organisation | Wellcome Trust |
| Department | KEMRI-Wellcome Trust Research Programme |
| Country | Kenya |
| Sector | Academic/University |
| PI Contribution | We have provided samples and data from the Entebbe Mother and Baby Study for work on the relationship between iron deficiency and malaria. |
| Collaborator Contribution | Our partners have assembled an international collaboration with data from four major cohorts and have conducted analyses on iron status and genetics. |
| Impact | Publications and conference presentations. PhD in progress for John Muriuki Two Masters degrees in progress. |
| Start Year | 2016 |
| Description | Uganda Schistosomiasis Multidisciplinary Research Center |
| Organisation | Uganda Virus Research Institute |
| Country | Uganda |
| Sector | Public |
| PI Contribution | This is an NIH-funded Tropical Medicine Research Center which I lead. |
| Collaborator Contribution | Partners lead on various aspects of the work, through Working Groups. |
| Impact | Uganda Schistosomiasis Symposium held March 2023 |
| Start Year | 2022 |
| Description | Uganda Schistosomiasis Multidisciplinary Research Center |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | This is an NIH-funded Tropical Medicine Research Center which I lead. |
| Collaborator Contribution | Partners lead on various aspects of the work, through Working Groups. |
| Impact | Uganda Schistosomiasis Symposium held March 2023 |
| Start Year | 2022 |
| Title | TB042 tuberculosis vaccine trial |
| Description | Tuberculosis candidate vaccine regimen ChAdOx1 85A/MVA85A was compared to BCG for boosting TB-specific responses in Ugandan adolescents |
| Type | Therapeutic Intervention - Vaccines |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2022 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | Evidence in support of further development of tuberculosis vaccines of this type. |
| Description | Commissioning of MRC/UVRI & LSHTM Clinical Research Facility |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Commissioning of new clinical research facility |
| Year(s) Of Engagement Activity | 2022 |
| Description | Ebola Vaccine Trial meetings |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Discussions on vaccine trials for the Sudan Ebola Vaccine |
| Year(s) Of Engagement Activity | 2022,2023 |
| Description | Engagement with CHI-S target communities |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | We undertook a project engaging target communities for Controlled human infection studies to understand knowledge of schistosomiasis, attitudes to controlled infection studies and issues that might arise for participants from endemic communities during such studies; we tested information to be provided, and the consenting process. |
| Year(s) Of Engagement Activity | 2019,2020 |
| Description | Engagement with district authorities in planning of the POPVAC B trial in Jinja District |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | An on-going series of meetings with district health and education authorities to plan and then conduct the POPVAC B trial in Jinja district. |
| Year(s) Of Engagement Activity | 2020,2021,2022 |
| Description | Legal status of controlled human infection studies in Uganda |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | We met with lawyers in Uganda and obtained a legal opinion to the effect that there is no legal barrier to controlled human infection with schistosomes in Uganda. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Meeting with Koome island community leaders |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Study participants or study members |
| Results and Impact | Two meetings were held (April and July) with community leaders from island communities who will take part in the study |
| Year(s) Of Engagement Activity | 2018 |
| Description | Meeting with UNEPI |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | A meeting was held with colleagues from the Uganda National Expanded Programme on Immunisation to discuss project plans |
| Year(s) Of Engagement Activity | 2018 |
| Description | Meeting with policy makers |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Meeting with the manager of the Uganda Tuberculosis Control Programme to share results. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Meetings at Koome schools |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Study participants or study members |
| Results and Impact | A series of meetings were held with teachers, parents and community members to inform them about the study |
| Year(s) Of Engagement Activity | 2018 |
| Description | Mukono District meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Discussions were held with Mukono district leaders about the project plans |
| Year(s) Of Engagement Activity | 2018 |
| Description | Open Day for Secondary Schools |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | We led an Open Day at the Uganda Virus Research Institute, in collaboration with Makerere University. About 900 senior secondary students attended with their teachers. The guest of honour was the Minister of State for Education and Sports (Higher Education). |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://www.muii.org.ug/ |
| Description | Outbreaks stakeholders workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This was a stakeholders' workshop for researchers and outbreak control implementers from East Africa, to share activities and discuss needs in terms of research and implementation capacity for the control of outbreak diseases |
| Year(s) Of Engagement Activity | 2019 |
| Description | POPVAC Programme Steering Committee Meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Steering Committee meetings are held annually. Members include representatives of the District Health Leadership and of the Vector Control Division of the Ministry of Health. Also international experts. |
| Year(s) Of Engagement Activity | 2018,2019,2020,2021 |
| Description | Programme staff retreat |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | Programme staff retreat. Team building and education in financial management |
| Year(s) Of Engagement Activity | 2022 |
| Description | SYMPOSIUM. "Research in Context: contributing to the SDGs" |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | We held a symposium to discuss how research, particularly laboratory based health research, in Uganda could contribute to the Sustainable Development Goals. We had excellent keynote addresses from the WHO representative to Uganda, and from Dr Annettee Nakimuli, an obstetrician and rising research star on maternal and neonatal health. We also had a dynamic panel discussion on translating laboratory work into implementable tools and products. As well as short presentations from research students and fellows. There was interaction with the media. |
| Year(s) Of Engagement Activity | 2019 |
| URL | http://www.muii.org.ug/ |
| Description | Symposium |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Dissemination meeting for researchers from the HATUA consortium (GCRF-funded, on Anti-Microbial Resistance) and MUII-plus (DELTAS Africa consortium, research and capacity building in infection and immunity). Attended by Uganda's Honourable Minister for Science, Technology and Innovation. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Symposium: Science for Africa: looking to the 2020s |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | A symposium held as part of the Annual General Meeting of our DELTAS-funded capacity building programme, MUII-plus |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.muii.org.ug/ |
| Description | UNEPI EPI Technical working committee membership |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | The POPVAC project leader has been able to participate in the Uganda National Expanded Programme on Immunisation Technical working committee in order to share our research and keep abreast of national policy developments. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Uganda Schistosomiasis Symposium |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | A three-day symposium attended by national and international colleagues in schistosomiasis research and in the development of controlled human infection studies. Attended by researchers in person and online, school students, ministry of health colleagues and representatives of the media. Academic talks and demonstrations. |
| Year(s) Of Engagement Activity | 2023 |
| Description | VAnguard Global Health Group Launch event |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | An event engaging collaborators, community members and other stakeholders to initiate and plan for the NIHR Global Health Group, VAnguard |
| Year(s) Of Engagement Activity | 2022 |
| Description | Vaccine Research Theme retreat |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | A Theme retreat in preparation for the forthcoming quinquennium of the MRC/UVRI and LSHTM |
| Year(s) Of Engagement Activity | 2023 |
| Description | Wellcome Trust meeting: Use and utility of human infection study data in the vaccine licensure pathway |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Scientific workshop |
| Year(s) Of Engagement Activity | 2022 |